# JUL 2 2 2004 U

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Barnes, Thomas M., et al. (as amended)

Apprication No.:

10/042,431

Group

1652

Filed: For:

October 25, 2001

No.: Examiner:

Nashed, Nashaat T.

METHOD OF IDENTIFYING INHIBITORS OF THE HUMAN LIPASE

TANGO 294 (as amended)

## Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## **DEPOSIT DECLARATION**

Sir:

- I, Mario Cloutier, hereby declare that:
- 1. I am an agent of record in the above-identified patent application.

#### CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

#### MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

×

with sufficient postage as first class mail.

as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION transmitted by facsimile to the Patent and Trademark Office.

Date:

July 19, 2004

Sean Hunziker

Signature

(type or print name of person certifying)

\*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

- 2. Plasmids containing clone EpT294, encoding human TANGO 294 polypeptides described in the above-identified patent application, were deposited with the American Type Culture Collection (ATCC®), 10801 University Boulevard, Manassas, VA 20110-2209, on April 20, 1999 under the terms of the Budapest Treaty and assigned (composite) ATCC® Accession Number 207220.
- 3. Upon granting of a patent on the above-identified patent application, all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed.

I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the instant patent application or any patent issued thereon.

Respectfully submitted,

July 19, 2004

MILLENNIUM PHARMACEUTICALS, INC.

/Mario Cloutier

Limited Recognition Under 37 C.F.R. §10.9(b)

40 Landsdowne Street Cambridge, MA 02139 Telephone - 617-577-3522

Facsimile - 617-551-8820



# BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATE PATENT AND TRADEMARK OFFICE

# LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Mario Cloutier is hereby given limited recognition under 37 CFR, 10.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: March 1, 2005

Harry I. Moatz

Director of Enrollment and Discipline